Licensed Practical Nurse in Oregon, OH Accepting Medicare

7 Licensed Practical Nurse nurses found. Showing 1 - 7

Tamara Lynn Carruthers, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2600 Navarre Ave, Oregon, OH 43616 Phone: 419-696-7200

Ms. Torri Lynne Ollivier, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1325 N Stadium Rd, Oregon, OH 43616 Phone: 419-704-3197    Fax: 419-698-1561

Aymee Staton, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2526 Granton Pl, Oregon, OH 43616 Phone: 419-283-9060

Mrs. Crystal Renee Austin, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 929 Cardinal Bay Drive, Oregon, OH 43616 Phone: 419-697-6283

Lauren Coberley, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2261 Brown Rd, Oregon, OH 43616 Phone: 419-290-9458

Sierra N Green, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3953 Navarre Ave, Oregon, OH 43616 Phone: 419-698-4521

Angela Pirolli, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 456 South Stephen, Oregon, OH 43616 Phone: 419-509-2797

News Archive

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

CTI BioPharma Corp. today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX (arsenic trioxide).

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.

GenVec malaria vaccine initiative and the U.S. Naval Medical Research Center has announced partnership for malaria vaccine

GenVec, Inc., PATH's Malaria Vaccine Initiative (MVI), and the U.S. Naval Medical Research Center (NMRC) today announced a dynamic partnership to assess whether five malaria antigens, or proteins, can generate strong immune responses alone or in combination. This partnership will advance and expand the ongoing malaria vaccine development program between GenVec and NMRC. Malaria is one of the world's three leading infectious disease killers.

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has opened offices in Chengdu and Guangzhou, China to support a growing requirement for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.

Read more Medical News

› Verified 1 days ago